双氢青蒿素/哌喹治疗喀麦隆无并发症恶性疟的疗效
该研究在喀麦隆雅温得对138例无并发症恶性疟患者进行42天随访,双氢青蒿素/哌喹经PCR校正后疗效为100%。未发现青蒿素或哌喹耐药证据,提示该组合在无耐药地区可持续有效。
要点
- 双氢青蒿素/哌喹经PCR校正后疗效达100%。
- 未检测到plasmepsin2基因扩增,体外药敏全部敏感。
核心结论
- 双氢青蒿素/哌喹在喀麦隆雅温得治疗无并发症恶性疟疗效优异,未发现青蒿素或哌喹耐药证据。
研究设计与样本
- 前瞻性随访研究,纳入138例无并发症恶性疟患者,随访42天。
- 124例患者测定第7天哌喹浓度,150例检测kelch13基因多态性,148例检测plasmepsin2基因扩增。
- 87例样本进行体外生存试验检测对双氢青蒿素和哌喹的敏感性。
主要发现
- 双氢青蒿素/哌喹治疗经PCR校正后疗效为100%。
- 再感染与第7天哌喹浓度变化无关。
- 未观察到plasmepsin2基因扩增(0/148)。
- 体外生存试验的87例样本均对双氢青蒿素和哌喹敏感。
临床怎么用
- 在喀麦隆等无青蒿素和哌喹耐药地区,双氢青蒿素/哌喹可作为可持续的治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dihydroartemisinin/piperaquine is increasingly used for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. The efficacy of this combination in Cameroon is poorly documented, while resistance to dihydroartemisinin/piperaquine readily spreads in Southeast Asia. OBJECTIVES: This study evaluated the clinical efficacy of dihydroartemisinin/piperaquine in Cameroon, as well as the molecular profile and phenotypic susceptibility of collected isolates to dihydroartemisinin and piperaquine. PATIENTS AND METHODS: Dihydroartemisinin/piperaquine efficacy in 42 days was followed-up for 138 patients presenting non-complicated falciparum malaria. Piperaquine concentration was determined at day 7 for 124 patients. kelch13 gene polymorphisms (n = 150) and plasmepsin2 gene amplification (n = 148) were determined as molecular markers of resistance to dihydroartemisinin and piperaquine, respectively. Parasite susceptibility to dihydroartemisinin and piperaquine was determined using validated in vitro survival assays. RESULTS: The efficacy of dihydroartemisinin/piperaquine treatment was 100% after PCR correction. The reinfections were not associated with a variation of piperaquine concentration at day 7. Ninety-six percent (144/150) of the samples presented a WT allele of the kelch13 gene. Two percent (3/150) presented the non-synonymous mutation A578S, which is not associated with resistance to dihydroartemisinin. No duplication of the plasmepsin2 gene was observed (0/148). All the samples tested in vitro by survival assays (n = 87) were susceptible to dihydroartemisinin and piperaquine. CONCLUSIONS: Dihydroartemisinin/piperaquine has demonstrated excellent therapeutic efficacy with no evidence of emerging artemisinin or piperaquine resistance in Yaoundé, Cameroon. This observation suggests that dihydroartemisinin/piperaquine could be a sustainable therapeutic solution for P. falciparum malaria if implemented in areas previously free of artemisinin- and piperaquine-resistant parasites, unlike Southeast Asia.
引用
- Mairet-Khedim M, Nsango S, Ngou C, et al. Efficacy of dihydroartemisinin/piperaquine in patients with non-complicated Plasmodium falciparum malaria in Yaoundé, Cameroon. J Antimicrob Chemother. 2021. PMID: 34453535. doi:10.1093/jac/dkab281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。